2025
Shafrin J, Wang S, Sharma K, Spurrier K, Nordyke RJ . 2025. Will the Institute for Clinical and Economic Review’s shared savings approach decrease value-based prices most for the most severe diseases? Value Health 28(1):25-30; doi: 10.1016/j.val.2024.09.002 . PMID: 39357669.
View Abstract
Publication: Manuscripts
/ Topics: Health Economics and Outcomes Research (HEOR)
Patterson JA, Motyka J, Salih R, Nordyke RJ , O’Brien JM, Campbell JD. 2025. Subsequent indications in oncology drugs: Pathways, timelines, and the Inflation Reduction Act. Ther Innov Regul Sci 59(1):102-111; doi: 10.1007/s43441-024-00706-6 . PMID: 39369117.
View Abstract
Publication: Manuscripts
/ Topics: drug development
Lipworth L, Panko JM, Allen BC, Mumma MT, Jiang X , Vincent MJ, Bare JL, Antonijevic T, Vivanco SN, Marano DE, Suh M , Cohen S, Mittal L, Proctor DM. 2025. Lung cancer mortality among aircraft manufacturing workers with long-term, low-level, hexavalent chromium exposure. J Occup Environ Hyg 22(3):214-227 ; doi: 10.1080/15459624.2024.2439817 . PMID: 39773194.
View Abstract
Publication: Manuscripts
/ Topics: Cancer , chromium , Exposure Assessment , Occupational
2024
Kim A, Cong Z, Jazieh A-R, Church TR, Reichert H , Nicholson G, Fryzek J, Cohen SS. 2024. Estimating the incremental population health impact of a multi-cancer early detection (MCED) test to complement existing screening among elevated risk populations with multiple cancer risk factors: A mathematical modeling study. BMC Health Serv Res 24(1):1584; doi: 10.1186/s12913-024-12037-1 . PMID: 39695574.
View Abstract
Publication: Manuscripts
/ Topics: Cancer , Epidemiology
Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693 , ISPOR Europe 2024, November 2024.
View Abstract
Publication: Abstracts and Presentations
/ Topics: Health Economics and Outcomes Research (HEOR) , Metachromatic leukodystrophy (MLD)
Haselkorn T, Hughes W, Lennox A, Schara-Schmidt U, Roca A, Miller B, Jensen I , et al. Real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. Abstract PCR257 , ISPOR EU 2024 (Top 5% Finalist).
View Abstract
Publication: Abstracts and Presentations
/ Topics: Health Economics and Outcomes Research (HEOR)
Haselkorn T, Roca A, Miller B, Jensen I , Solomon F, Sanchez-de la Rosa R, Picart JM, Nascimento A. A real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in Spain. Presented at LXXVI Reunion Annual de la Sociedad Espanola de Nurologica, 19–23 November 2024.
Publication: Abstracts and Presentations
/ Topics: Health Economics and Outcomes Research (HEOR)
Suh M , Mittal L, Brorby G, Pastula S, Vincent M, Proctor D. Epidemiology is critical in advancing cumulative impact assessment (CIA) research: A pilot study in San Antonio, Texas. International Society of Exposure Science, Montreal, Canada, October 2024.
View Abstract
Publication: Abstracts and Presentations
/ Topics: Air Quality , Epidemiology
Kelsh M , Bylsma LC, Jiang X, Movva N , Sacks NC . To be an orphan disease or not to be: An evaluation of prevalence estimates for cancers near the orphan status threshold and implications for orphan drug planning. International Society for Pharmacoepidemiology, 40th Annual Meeting, Berlin, Germany, August 2024.